当前位置: X-MOL 学术Cancer Discov. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Celgene Targets Blood Cancers with Major Buys
Cancer Discovery ( IF 29.7 ) Pub Date : 2018-03-01 , DOI: 10.1158/2159-8290.cd-nb2018-007
American Association for Cancer Research

Celgene acquired Juno Therapeutics for $9 billion and is spending up to $7 billion on Impact Biomedicines in an effort to diversify its hematology portfolio with chimeric antigen receptor T-cell therapies and a JAK2 inhibitor before its best seller, lenalidomide, faces competition from generics.



中文翻译:

Celgene大量购买针对血液癌

Celgene以90亿美元的价格收购了Juno Therapeutics,并将斥资70亿美元收购Impact Biomedines,以使其血液学产品系列多样化,包括嵌合抗原受体T细胞疗法和JAK2抑制剂,而其最畅销的产品来那度胺则面临来自仿制药的竞争。

更新日期:2018-03-02
down
wechat
bug